1️⃣ BeOne put BCL-2 into MCL The FDA granted accelerated approval to BeOne’s Beqalzi for relapsed or refractory mantle cell lymphoma after at least two prior lines, including a BTK inhibitor.
💡 Why it matters This gives BeOne the first U.S. BCL-2 label in MCL, with CLL still the larger competitive prize against AbbVie and Roche’s Venclexta.
☕ Coffee talk Does MCL become proof of pharmacology, or just the narrow door BeOne needed before CLL?
2️⃣ Taiho made frontline AML fully oral The FDA approved Inqovi plus venetoclax for newly diagnosed AML patients aged 75 or older, or otherwise ineligible for intensive induction chemotherapy.
💡 Why it matters The label shifts part of low-intensity AML care from parenteral HMA regimens toward an all-oral option, with 41.6% complete remissions in ASCERTAIN-V.
☕ Coffee talk If the regimen moves out of the infusion chair, who actually captures the convenience premium?
3️⃣ Pfizer widened Hympavzi in Europe The European Commission approved Hympavzi for adults and adolescents with hemophilia A or B with inhibitors, expanding the once-weekly anti-TFPI franchise.
💡 Why it matters Inhibitor patients are harder to treat and commercially cleaner than the base hemophilia label. Pfizer now has an EU foothold while the U.S. sBLA is still pending.
☕ Coffee talk How much of this market still wants factor logic once a weekly pen is good enough?